Skip to content

GlobalLawDBby GenieAI

Laws Search Sanctions Map Data Developers

Search the text of the law

Log in Get an API key

Laws Search Sanctions Map Data Developers

Log in Get an API key

The Global Law Database. Free to read, built for people and AI agents.

Explore

All laws
Search the text
Sanctions
Map of connections
Compare UK and EU

Developers

AI agents (MCP)
REST API
Bulk data
API keys

Coverage

United Kingdom
European Union
United States
Canada
Australia
France
Germany
Netherlands
Spain
Austria
Norway
Finland
Switzerland
Ireland

GlobalLawDB is made by GenieAI, London. It is not legal advice: check the official text before relying on it. Text comes from official publishers under their licences, listed on the Data page.

ThemeMatch my systemLightDark

European Union
M2Beauté Cosmetics GmbH v Bundesrepublik Deutschland (C-616/20)
Consideration of the questions referred
The second and third questions
41

M2Beauté Cosmetics GmbH v Bundesrepublik Deutschland (C-616/20)

Judgment of 13 Oct 2022law://eu/cjeu/2020/c-616-20/para_41@2026-11-10

41In the present case, Article 1(2)(b) of Directive 2001/83 must be interpreted in the light of the objective pursued by that directive, namely to ensure a high level of protection of human health.

Source: EUR-Lex, © European Union, 1998-2026. Reuse authorised under Decision 2011/833/EU.

Key facts

Court: Court of Justice · Second Chamber
Case: C-616/20 · ECLI:EU:C:2022:781
Decided: 13 Oct 2022
Procedure: Preliminary reference · referred by the Verwaltungsgericht Köln (Administrative Court, Cologne, Germany)
Applicant: M2Beauté Cosmetics GmbH
Defendant: Bundesrepublik Deutschland
Rapporteur: N. Wahl
Advocate General: T. Ćapeta
Bench: 5 judges
A. Prechal, M.L. Arastey Sahún, F. Biltgen, N. Wahl, J. Passer
Language: German
Official: CURIA · EUR-Lex 62020CJ0616

Topics

Pharmaceutical and cosmetic products

History · 1 version

13 Oct 2022Reading

Connections

Interprets 1: Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use
Cited by 2: Direktor na Direktsia „Obzhalvane i danachno-osiguritelna praktika“ Sofia pri Tsentralno upravlenie na Natsionalna agentsia za prihodite v „Bulgarian posts“ EAD (C-785/23); Cassella-med GmbH & Co. KG and MCM Klosterfrau Vertriebsgesellschaft mbH v Verband Sozialer Wettbewerb eV (C-589/23)3 provisions
Cites 10: Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use; NW v Landespolizeidirektion Steiermark (C-368/20); Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products (recast) (Text with EEA relevance); Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (Text with EEA relevance); Hecht-Pharma GmbH v Staatliches Gewerbeaufsichtsamt Lüneburg (C-140/07); Chemische Fabrik Kreussler & Co. GmbH v Sunstar Deutschland GmbH, formerly John O. Butler GmbH (C-308/11); Laboratoires Lyocentre v Lääkealan turvallisuus- ja kehittämiskeskus and Sosiaali- ja terveysalan lupa- ja valvontavirasto (C-109/12); Council Regulation (EEC) No 2309/93 of 22 July 1993 laying down Community procedures for the authorization and supervision of medicinal products for human and veterinary use and establishing a European Agency for the Evaluation of Medicinal Products; BIOS Naturprodukte GmbH v Saarland (C-27/08); Markus D. and G (C-358/13)